| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.
|
Neurourol Urodyn
|
2002
|
22.80
|
|
2
|
The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.
|
Urology
|
2003
|
9.92
|
|
3
|
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.
|
Am J Obstet Gynecol
|
2002
|
4.31
|
|
4
|
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
|
Cancer
|
2002
|
3.72
|
|
5
|
Bladder Pain Syndrome Committee of the International Consultation on Incontinence.
|
Neurourol Urodyn
|
2010
|
1.55
|
|
6
|
Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.37
|
|
7
|
Economic burden of urgency urinary incontinence in the United States: a systematic review.
|
J Manag Care Pharm
|
2014
|
1.36
|
|
8
|
Overactive bladder and painful bladder syndrome: there need not be confusion.
|
Neurourol Urodyn
|
2005
|
1.23
|
|
9
|
Out-of-pocket expenses and treatment choice for men with prostate cancer.
|
Urology
|
2012
|
0.92
|
|
10
|
Alteration of contractile and regulatory proteins following partial bladder outlet obstruction.
|
Scand J Urol Nephrol Suppl
|
2004
|
0.91
|
|
11
|
Can we prevent incontinence? ICI-RS 2011.
|
Neurourol Urodyn
|
2012
|
0.91
|
|
12
|
PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level.
|
Urol Oncol
|
2005
|
0.88
|
|
13
|
Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.
|
J Urol
|
2002
|
0.87
|
|
14
|
Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.85
|
|
15
|
Fourth international consultation on incontinence-research society 2013.
|
Neurourol Urodyn
|
2014
|
0.84
|
|
16
|
Urgency as the cardinal symptom of overactive bladder: a critical analysis.
|
World J Urol
|
2009
|
0.81
|
|
17
|
The International Consultation on Incontinence, Research Society (ICI-RS).
|
Neurourol Urodyn
|
2010
|
0.78
|
|
18
|
3rd International Consultation on Incontinence--Research Society 2011.
|
Neurourol Urodyn
|
2012
|
0.77
|
|
19
|
Lipid signaling changes in smooth muscle remodeling associated with partial urinary bladder outlet obstruction.
|
Neurourol Urodyn
|
2006
|
0.76
|
|
20
|
Do patients with symptoms and signs of lower urinary tract dysfunction need a urodynamic diagnosis? ICI-RS 2013.
|
Neurourol Urodyn
|
2014
|
0.76
|
|
21
|
Authors' response: Re: Rosier PFWM, Kirschner-Hermanns R, Svihra J, Homma Y, Wein AJ. ICS teaching module: Analysis of voiding, pressure flow analysis (basic module). Neurourol Urodyn. 2014 Sep 11. doi: 10.1002/nau.22660.
|
Neurourol Urodyn
|
2015
|
0.75
|
|
22
|
Is it possible to make cross-study comparisons of urinary continence rates in patients with overactive bladder?
|
Curr Med Res Opin
|
2005
|
0.75
|
|
23
|
Current pharmacotherapy of nocturia.
|
Expert Opin Pharmacother
|
2013
|
0.75
|
|
24
|
The 2nd International Consultation on Incontinence, Research Society (ICI-RS) meeting 2010.
|
Neurourol Urodyn
|
2011
|
0.75
|